Pharmacokinetics, side effects and efficacy of IBPS: An integrative review

Authors

  • Ana Laura da Costa Medeiros Centro Universitário Metropolitano da Amazônia
  • Sandro Cavalcante Raiol Centro Universitário do Estado do Pará
  • Danielli Valeria Diniz Felisberto Centro Universitário Metropolitano da Amazônia

DOI:

https://doi.org/10.33448/rsd-v12i8.42973

Keywords:

Proton pump inhibitors; Adverse effects; Efficiency.

Abstract

Proton pump inhibitors (PPIs) are the most widely used drugs in the world. Currently, six PPIs are available on the market: dexlansoprazole, esomeprazole, lansoprazole, pantoprazole, omeprazole and rabeprazole. Their half-life is approximately 1 hour and they are biotransformed in the liver through CYP2C19 and CYP3A4 isoforms. The objective was to carry out a literature review regarding the pharmacokinetics, side effects and effectiveness of IBPS. The methodology was based on an integrative review, which considered the databases Medline, Lilacs, Scielo, Pubmed and Google Scholar, articles in English, Portuguese and Spanish, published from 2011 to 2019. PPIs are abrasive drugs used in the treatment of diseases applied to gastric acid secretion, having a good potential in inhibiting acid secretion, which may take up to 3 to 4 days. PPIs are generally well tolerated, and the most common side effects are headache, abdominal pain, nausea, and diarrhea. PPIs produce significantly more effective and prolonged acid suppression than H2 receptor antagonists and can maintain gastric pH above 4 for up to 16 to 18 h/day. In the context of what has been presented, PPIs have been the drugs of first choice in the treatment of peptic diseases. They are generally well accepted, and care should be taken in patients who take this medication for 1 year or more.

References

Alves Junior, G. L., Galindo Neto, G., Oliveira, R. C., Teixeira, J. P., Alves, M. M. S. A., Pereira, V. M. P., Carvalho, M. A. N. C., Cardoso, V. L. de S. C., & Campos, A. L. B. C. (2022). O uso de inibidor de bomba de prótons em pacientes internados em unidades de terapia intensiva: uma revisão integrativa. Research, Society and Development, 11(14), e464111436763. https://doi.org/10.33448/rsd-v11i14.36763

Araújo, L. S., Araujo, B. M., Guimarães, C. S., Fróes, D. N. S., Maia, E. C. S., Hoffmann, G., & Leite, N. A. A. (2021). Inibidores de Bomba de Prótons: vantagens e desvantagens do uso prolongado. Revista Eletrônica Acervo Científico, 34, e8662-e8662.

Arora, P., Gupta, A., Golzy, M., Patel, N., Carter, R. L., Jalal, K., & Lohr, J. W. (2016). Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC nephrology, 17, 1-8.

Barroso, C. R. D., Guedes, T. R., Gomes, L. S., Silvestre, V. A., & Cury, S. E. V. (2018). Relação entre o uso de inibidores de bomba de prótons e o desenvolvimento de demência senil: uma revisão de literatura. Cadernos UniFOA, 13(37), 136-146.

Braga, M. P., da Silva, C. D. B., & Adams, A. I. H. (2011). Inibidores da bomba de prótons: revisão e análise farmacoeconômica. Saúde (Santa Maria), 19-32.

Brinkworth, M. D., Aouthmany, M., & Sheehan, M. (2016). Histamine 2 receptor antagonists and proton pump inhibitors. Dermatitis, 27(3), 100-109.

Brito, A. L. S., Moreira, E. S., & Gonçalves, K. A. M. (2021). Os Riscos da Utilização Inadequada do Omeprazol: Uma revisão bibliográfica The Risks of Misuse of Omeprazole: A Literature Review. Brazilian Journal of Development, 7(12), 113207-113215.

Cardona-Ospina, J. A., Medina-Morales, D. A., Rodríguez-Morales, A. J., & Machado-Alba, J. E. (2016). Efectos adversos a largo plazo de los inhibidores de la bomba de protones: Perspectiva desde la medicina basada en la evidência. Revista colombiana de Gastroenterología, 31(4), 403-408.

Chen, L., Chen, Y., & Li, B. (2016). The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Scientific Reports, 6(1), 32126.

De Lima, A. P. V., & Dos Anjos Neto Filho, M. Á. R. I. O. (2013). Efeitos em longo prazo de inibidores da bomba de prótons. Brazilian Journal of Surgery & Clinical Research, 5(3).

De Oliveira, G. K. S., Santana, L. F., Guimarães, T. A., Soares, P. H. A., Lommez, T. C. M., Barbosa, C. N. S., ... & Caribé, T. E. G. (2018). O uso do Omeprazol: uma avaliação dos efeitos da administração prolongada do medicamento. Revista Eletrônica Acervo Saúde/Electronic Journal Collection Health ISSN, 2178, 2091.

Gomm, W., von Holt, K., Thomé, F., Broich, K., Maier, W., Fink, A., & Haenisch, B. (2016). Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA neurology, 73(4), 410-416.

Götz, M., & Nitschmann, S. (2019). Prevention of gastrointestinal bleeding by means of proton pump inhibitors. Der Internist, 60, 545-548.

Gyawali, C. P. (2017). Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Current gastroenterology reports, 19, 1-10.

Haastrup, P. F., Thompson, W., Søndergaard, J., & Jarbøl, D. E. (2018). Side effects of long‐term proton pump inhibitor use: a review. Basic & clinical pharmacology & toxicology, 123(2), 114-121.

López-Colombo, A., Pacio-Quiterio, M. S., Jesús-Mejenes, L. Y., Rodríguez-Aguilar, J. E. G., López-Guevara, M., Montiel-Jarquín, A. J., ... & Ávila-Jiménez, L. (2017). Factores de riesgo asociados a recaída de enfermedad por reflujo gastroesofágico en pacientes de primer nivel de atención exitosamente tratados con inhibidor de la bomba de protones. Revista de Gastroenterología de México, 82(2), 106-114.

Martins, R. F., & Bonatto, M. W. (2014). Pólipos gástricos estão relacionados ao uso crônico de inibidores de bomba de próton? GED gastroenterol. endosc. dig, 34-37.

Morschel, C. F., Mafra, D., & Eduardo, J. C. C. (2018). Inibidores da bomba de prótons e sua relação com a doença renal. Brazilian Journal of Nephrology, 40, 301-306.

Mössner, J. (2016). The indications, applications, and risks of proton pump inhibitors: A review after 25 years. Deutsches Ärzteblatt International, 113(27-28), 477.

Oliveira, E. L. D., Oliveira, J. R. D., Moreira, D. R., Rabelo, R. D. O., Belém, É. M. S., & Oliveira, E. L. D. (2015). aracterísticas farmacocinéticas e farmacodinâmicas dos inibidores de bombas de protóns (IBPs). Anais da Mostra Científica da Farmácia 2015; 2(2):9.

Seixas, A. M. B. B. (2016). Efeitos negativos dos inibidores da bomba de protões (Dissertação de mestrado em medicina).

Strand, D. S., Kim, D., & Peura, D. A. (2017). 25 years of proton pump inhibitors: a comprehensive review. Gut and liver, 11(1), 27.

Tanus‐Santos, J. E., & Pinheiro, L. C. (2019). Proton pump inhibitors: new mechanisms of action. Basic & Clinical Pharmacology & Toxicology, 125(2), 87-88.

Whalen, K., Finkel, R., & Panavelil, T. A. (2016). Farmacologia Ilustrada. (6a ed.) Artmed Editora.

Zaterka, S. & Eisig, J. N. (2016). Tratado de gastroenterologia: da graduação à pós-graduação. Ed. Atheneu.

Published

21/08/2023

How to Cite

MEDEIROS, A. L. da C. .; RAIOL, S. C. .; FELISBERTO, D. V. D. . Pharmacokinetics, side effects and efficacy of IBPS: An integrative review. Research, Society and Development, [S. l.], v. 12, n. 8, p. e10912842973, 2023. DOI: 10.33448/rsd-v12i8.42973. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/42973. Acesso em: 17 may. 2024.

Issue

Section

Health Sciences